In patients with thymic epithelial tumors receiving immune checkpoint inhibitors, each doubling of creatine kinase was associated with higher all-cause mortality (HR 1.22).
Cohort (n=31)
No
In patients with thymic epithelial tumors receiving immune checkpoint inhibitors, there is a high incidence of severe myocarditis, particularly in those with thymoma, contributing to substantial cardiovascular mortality.
Effect estimate: HR 1.22 (95% CI 1.01-1.47)
p-value: p=0.038
In this cohort of TET patients receiving ICI therapy, myocarditis occurred frequently in thymoma patients. Overall mortality was substantial in TET patients, with nearly half of the deaths attributable to cardiovascular causes. These findings highlight the need for vigilant cardiovascular monitoring in all TET patients undergoing ICI therapy and warrant confirmation in larger multicenter studies.
Zeng et al. (Thu,) conducted a cohort in Thymic epithelial tumors (TET) (n=31). Immune checkpoint inhibitors (ICI) was evaluated on All-cause mortality (HR 1.22, 95% CI 1.01-1.47, p=0.038). In patients with thymic epithelial tumors receiving immune checkpoint inhibitors, each doubling of creatine kinase was associated with higher all-cause mortality (HR 1.22).